Antisoma: Novartis Will Include Non-Squamous NSCLC Patients In Phase III ASA404 Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to include both squamous and non-squamous cancer types doubles the study population and indicates ASA404 may compete with Avastin.
You may also be interested in...
Novartis Launches Phase III Trial For NSCLC Candidate
Called a potential blockbuster by Novartis, ASA404 will be tested in 1,200 patients to measure overall survival.
Novartis Launches Phase III Trial For NSCLC Candidate
Called a potential blockbuster by Novartis, ASA404 will be tested in 1,200 patients to measure overall survival.
Oxigene Reports Positive Data For Zybrestat In Platinum-Resistant Ovarian Cancer
Novel vascular disrupting agent is also in studies for anaplastic thyroid cancer and macular degeneration.